Skip to main content

Behçet Disease

Findings from a recent study showed an IL-17 inhibitor was associated with complete or partial response among patients with a mucosal and articular phenotype of Behçet syndrome who were refractory to treatment with traditional therapies and tumor necrosis factor inhibitors.
Findings from a recent prospective study showed patients with Behçet disease treated with a biologic agent experienced significant improvements in arthritis and mucocutaneous manifestations.
The Dermatologist
The FDA approved a new treatment option for patients with oral ulcers associated with Behçet disease.
Rheumatology Consultant
After results of a phase 2 trial showed that apremilast can reduce the incidence and severity of oral ulcers in patients with Behçet syndrome, researchers sought to determine whether the medication could do the same for patients with active ulcers but no major organ involvement.
A 15-year-old girl presented for a well-child visit. During the review of systems, she stated that she had had vaginal pain on and off since 8 years of age.
Back to Top